Amp Volatility Score
Catalyst Info & Data Links
TITLE: CDX-0159 for KIT/Mast Cell Diseases - Phase 1
ClinicalTrial.gov (NCT04548869): A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Urticaria or Symptomatic Dermographism
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-05-2020 2020 Third Quarter Financial Results
MECHANISM OF ACTION
CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease.
Updated by JM
CLDX, CELLDEX, CDX-0159, KIT/Mast Cell Diseases
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post